Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy
Cancer Science · 2024-04 · 115 (4) · 1048-1059
DOI: 10.1111/cas.16118 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 21.02.2024. Verfasst von Yuriko Minegishi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Proteomics Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Shimadzu Corporation, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
With significant advances in analytical technologies, research in the field of cancer immunotherapy, such as adoptive T cell therapy, cancer vaccine, and immune checkpoint blockade (ICB), is currently gaining tremendous momentum. Since the efficacy of cancer immunotherapy is recognized only by a minority of patients, more potent tumor‐specific antigens (TSAs, also known as neoantigens) and predictive markers for treatment response are of great interest. In cancer immunity, immunopeptides, presented by human leukocyte antigen (HLA) class I, play a role as initiating mediators of immunogenicity. The latest advancement in the interdisciplinary multiomics approach has rapidly enlightened us about the identity of the “dark matter” of cancer and the associated immunopeptides. In this field, mass spectrometry (MS) is a viable option to select because of the naturally processed and actually presented TSA candidates in order to grasp the whole picture of the immunopeptidome. In the past few years the search space has been enlarged by the multiomics approach, the sensitivity of mass spectrometers has been improved, and deep/machine‐learning‐supported peptide search algorithms have taken immunopeptidomics to the next level. In this review, along with the introduction of key technical advancements in immunopeptidomics, the potential and further directions of immunopeptidomics will be reviewed from the perspective of cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Proteomics Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Yuriko Minegishi, Yoshimi Haga, Koji Ueda
Förderung
- Japan Agency for Medical Research and Development
- Shimadzu Corporation
- Japan Society for the Promotion of Science
- Shimadzu
Zitieren
APA
Minegishi, Y., Haga, Y., & Ueda, K. (2024). Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy. Cancer Science, 115(4), 1048-1059. https://doi.org/10.1111/cas.16118
Vancouver
Minegishi Y, Haga Y, Ueda K. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy. Cancer Science. 2024;115(4):1048-1059. doi:10.1111/cas.16118
BibTeX
@article{Minegishi2024,
author = {Minegishi, Yuriko and Haga, Yoshimi and Ueda, Koji},
title = {Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {4},
pages = {1048--1059},
doi = {10.1111/cas.16118}
}
EUVIMED